AIVI0.650%
as of Jul 17
4502
UnknownTakeda Pharmaceutical Co Ltd
Close · 3M
+2.96%
Held by 1 AI ETF
Signal performance
Each tracked ETF's moves on this stock, grouped by fund. Returns are measured from the signal date to the latest close — hypothetical, no commissions or slippage.
Buy signals18
Win rate89% (16/18)
Avg buy return+3.17%
AIVI · Weight increase · 2d
The weight in Takeda Pharmaceutical within AIVI exhibited a gradual yet sustained increase, rising from 0.6249% to 0.6496% over three consecutive days. This incremental adjustment followed an earlier period of slight reduction, signaling a shift in the AI's assessment. This measured accumulation by WisdomTree's AI-managed international value ETF is noteworthy given Takeda’s current price of $33.74, which stands at 99% of its 52-week high. The AI overlay in AIVI likely re-evaluated Takeda’s position within its developed-international value pool, perceiving continued intrinsic value despite the higher price level and Takeda's modest positive returns of +1.4% over 30 days. Such a pattern suggests a strategic, data-driven conviction by the AI in Takeda's underlying fundamentals, consistent with the fund's international value style and periodic rebalancing schedule.
weight 0.625% → 0.650% (+0.025 pp)·stock up 7.6% in the 30 days before
Jul 17·entry 33.74·now 33.74Fresh
0.00%
since Jul 17
AIVI · Weight decrease · 4d
Takeda Pharmaceutical's current price of $32.61, representing 96% of its 52-week high, coupled with negative 30-day, 90-day, and 1-year returns of -0.8%, -0.5%, and -0.5% respectively, likely signals a diminished value proposition for the international value-focused AIVI ETF. This trend suggests the WisdomTree-managed fund's AI overlay began to reduce exposure to 4502 from July 8th as the stock approached its yearly peak without corresponding positive momentum. The AI selection mechanism, operating within its developed-international value-factor pool, likely reassessed Takeda's relative attractiveness given its recent performance and valuation metrics against other potential holdings. Consequently, the fund’s weight in Takeda progressively decreased from 0.6548% to 0.6249% over several rebalancing snapshots in July, reflecting a systematic re-evaluation aligned with its core international value mandate.
weight 0.655% → 0.625% (-0.030 pp)·stock up 3.4% in the 30 days before
Jul 15·entry 32.61·now 33.74
+3.45%
since Jul 15
AIVI · Weight decrease · 3d
The weight of Takeda (4502) in AIVI has seen a consecutive, gradual decrease from 0.6548% to 0.6331% over several trading days. This pattern suggests the AI overlay is making nuanced adjustments, even though the fund rebalances periodically rather than daily. With Takeda's price at $32.89, near 97% of its 52-week high, yet exhibiting only +0.3% to +0.4% returns across 30, 90, and 365 days, its value characteristics for this international value ETF likely diminished. Consequently, AIVI's AI appears to be systematically trimming its position as Takeda's valuation moves away from the desirable profile for this international value portfolio. This incremental reduction indicates the AI's continuous evaluation of holdings within its specific mandate.
weight 0.655% → 0.633% (-0.022 pp)·stock up 7.0% in the 30 days before
Jul 14·entry 32.89·now 33.74
+2.59%
since Jul 14
AIVI · Weight decrease · 2d
Takeda Pharmaceutical is currently priced at $32.75, positioned at 96% of its $33.98 52-week high, despite its 30-day return showing -0.4% and the one-year return at -0.1%. This current valuation, near the upper bound of its annual range even with recent negative returns, suggests a reduced "value" characteristic for the Japanese stock according to the AI managing AIVI. Consequently, the fund began decreasing its allocation to Takeda, with the weight falling consecutively from 0.6548% on 2026-07-08 to 0.6353% by 2026-07-13, aligning with AIVI's international value + AI overlay methodology.
weight 0.655% → 0.635% (-0.019 pp)·stock up 8.0% in the 30 days before
Jul 13·entry 32.75·now 33.74
+3.02%
since Jul 13
AIVI · Accumulation · 5d
AIVI’s detected pattern reveals a gradual accumulation of Takeda, with the fund’s allocation modestly increasing from 0.6218% to 0.6412% over a two-week period, punctuated by incremental additions and minor adjustments. This measured buildup occurs while Takeda trades at $33.12, registering a 30-day return of -0.5% but positioning the stock at 97% of its 52-week high. For an AI-managed ETF like AIVI, which targets developed-international value stocks and rebalances periodically, this behavior indicates the AI is identifying sustained intrinsic value in Takeda. The AI likely leverages the recent marginal price moderation as an opportune entry point to construct its position, aligning with a patient, fundamental-driven approach within its international value mandate.
weight 0.622% → 0.641% (+0.019 pp)·stock up 11.6% in the 30 days before
Jul 10·entry 33.12·now 33.74Fresh
+1.89%
since Jul 10
AIVI · Accumulation · 5d
Takeda Pharmaceutical’s modest 90-day and 1-year returns, each around +2.3%, alongside a recent 30-day dip of -1.4%, present a nuanced picture for WisdomTree’s AIVI, which targets international value. This international developed-market stock’s current price of $33.52, sitting at 99% of its 52-week high, did not deter the AI from initiating a gradual accumulation. The AI component of this fund, designed for an international value-factor pool, likely identified an intrinsic value in Takeda (4502) despite the seemingly elevated price point. This led to a measured increase in weight from 0.6217% to 0.6548% between late June and early July 2026, suggesting the AI’s model found a compelling entry point within its rebalancing schedule during a period of slight short-term decline.
weight 0.622% → 0.655% (+0.033 pp)·stock up 10.5% in the 30 days before
Jul 8·entry 33.52·now 33.74Fresh
+0.66%
since Jul 8
AIVI · Accumulation · 5d
WisdomTree’s AIVI, an AI-managed ETF selecting from an international developed-market value-factor pool, has shown a gradual accumulation in Takeda Pharmaceutical (4502). This methodical increase in allocation, spanning over two weeks from 0.6177% to 0.6506%, indicates the AI’s nuanced selection method is identifying Takeda as a compelling long-term holding within its approximately 100 international value stocks, operating within its periodic rebalancing schedule rather than daily adjustments. Despite Takeda's current price of $33.65 placing it at 99% of its 52-week high, the AI's algorithm within this value-focused framework appears to perceive fundamental undervaluation or a strong re-rating potential, justifying its persistent accumulation. The strategy of combining international value with an AI overlay permits AIVI to pinpoint such opportunities even when conventional metrics might suggest a stock is less "cheap," allowing for a more sophisticated interpretation of value.
weight 0.618% → 0.651% (+0.033 pp)·stock up 10.1% in the 30 days before
Jul 7·entry 33.65·now 33.74Fresh
+0.28%
since Jul 7
AIVI · Accumulation · 6d
WisdomTree's AIVI, deploying an AI overlay within its developed-international value mandate, appears to have identified Takeda Pharmaceutical (4502) as a fitting accumulation candidate for its portfolio. The gradual increase in Takeda's weight, observed from 0.6047% to 0.6585% over several trading days, indicates a considered accumulation by the AI algorithm, likely tied to the fund's periodic rebalance schedule. This deliberate accumulation occurred even as Takeda reached its 52-week high of $33.98, suggesting the AI's model perceived continued value or positive momentum within the international value framework, despite the higher price point. Given AIVI targets approximately 100 international developed-market value stocks, the consistent, incremental buying signals a specific conviction in Takeda as a foundational component meeting the AI's criteria.
weight 0.605% → 0.658% (+0.054 pp)·stock up 2.1% in the 30 days before
Jul 6·entry 33.98·now 33.74Fresh
-0.70%
since Jul 6
AIVI · Accumulation · 6d
Takeda Pharmaceutical, trading at $32.75 and near 96% of its 52-week high, has exhibited flat to negative price performance over the past year, with returns of -1.8% over 30 days, -0.1% over 90 days, and -0.1% over one year. This specific pattern of a developed-market stock maintaining a relatively high price point despite lagging returns across multiple horizons aligns with AIVI's international value + AI overlay methodology, suggesting the AI identified a potential mispricing or future appreciation. Consequently, AIVI gradually increased its allocation to Takeda from 0.5933% on June 22nd to 0.6385% by July 2nd, with the consistent buying activity occurring during this period of price stability and marginal decline. The WisdomTree-managed AI appears to have methodically built its position in 4502, selecting it as a value candidate within its ~100-stock international developed-market portfolio precisely when recent returns might deter conventional growth-focused strategies.
weight 0.593% → 0.638% (+0.045 pp)·stock down 1.5% in the 30 days before
Jul 2·entry 32.75·now 33.74Drifting
+3.03%
since Jul 2
AIVI · Accumulation · 5d
Takeda Pharmaceutical Co Ltd (4502) currently trades at $31.71, placing it near the upper end of its 52-week range of $29.69 to $33.98, at 93% of its high, yet it has experienced negative returns of -5.2% over the last 30 days and -3.2% over the past 90 days and one year. These recent pullbacks likely presented Takeda as a potential value opportunity within AIVI’s developed-international value factor pool. Operating with periodic rebalances, not daily, the AI manager incrementally increased the ETF’s holding of 4502 from 0.5933% to 0.6307% between June 22nd and July 1st. This gradual accumulation reflects the AI's assessment that the stock, despite its position near the top of its range, fits its international value mandate after recent declines.
weight 0.604% → 0.631% (+0.027 pp)·stock down 3.6% in the 30 days before
Jul 1·entry 31.71·now 33.74Drifting
+6.40%
since Jul 1
AIVI · Accumulation · 5d
The observed gradual accumulation of Takeda Pharmaceutical shares by AIVI, characterized by incremental increases from 0.5988% to 0.6270% over roughly two weeks, aligns with the ETF’s specific strategy. Operating with an AI overlay within a developed-international value-factor pool, the fund appears to be capitalizing on Takeda’s recent price dips, which saw a 5.7% negative return over 30 days. This pattern suggests the AI is identifying the current $31.72 price point as a more favorable entry for a stock meeting its value criteria, particularly given the stock’s prior negative performance across 30-day, 90-day, and one-year horizons. The fund’s continuous, small adjustments in its holding reflect the AI's ongoing assessment and tactical buying within its international value mandate.
weight 0.599% → 0.627% (+0.028 pp)·stock down 3.2% in the 30 days before
Jun 30·entry 31.72·now 33.74Drifting
+6.38%
since Jun 30
AIVI · Weight increase · 3d
Takeda Pharmaceutical (4502) trades at $31.26, approximately 92% of its 52-week high, following a 5.6% negative return over the last 30 days. These figures position the stock strongly within the value-factor criteria favored by AIVI, an ETF focused on developed-international value stocks. WisdomTree's AI system likely identified Takeda as increasingly attractive in its developed-international value-factor pool as its price compressed, leading to the consecutive weight increases observed from June 23rd to June 25th. This strategic allocation reflects the AI's specific application within an international value mandate, a comparatively underserved corner of the ETF market. The timing of the increased weighting coincides with Takeda's recent price performance, which would enhance its appeal to a value-oriented AI.
weight 0.593% → 0.622% (+0.028 pp)·stock down 6.1% in the 30 days before
Jun 25·entry 31.26·now 33.74Drifting
+7.93%
since Jun 25
AIVI · Weight increase · 2d
The gradual nature of the consecutive weight increase, from 0.5933% to 0.6177% observed in Takeda Pharmaceutical between June 22nd and June 24th, suggests a considered adjustment within AIVI’s portfolio. This measured accumulation, spread over several days, is consistent with WisdomTree’s strategy of periodic rebalancing, where an AI overlay identifies value-factor opportunities among international developed-market stocks. Takeda's price, at $31.54, now sits at 93% of its 52-week high, yet it records a uniform -3.7% return across 30-day, 90-day, and 1-year periods. This juxtaposition implies the AI perceives intrinsic value in the company, potentially anticipating a turnaround or recognizing a favorable entry point despite the recent short-term and long-term price weakness for the stock.
weight 0.593% → 0.618% (+0.024 pp)·stock down 7.2% in the 30 days before
Jun 24·entry 31.54·now 33.74Drifting
+6.96%
since Jun 24
AIVI · Weight decrease · 4d
The consecutive weight decrease in Takeda Pharmaceutical (4502) within AIVI, dropping from 0.6243% on June 10th to 0.5988% by June 16th, signals the AI manager's recalibration of the stock's fit for its international developed-market value factor pool. This sustained reduction suggests AIVI’s AI overlay, which rebalances periodically, assessed Takeda's valuation no longer aligned optimally with its value criteria during this specific period. The consistent unwinding of the position reflects the AI’s dynamic re-evaluation of Takeda's fundamental attractiveness relative to prevailing market prices. Consequently, Takeda's profile as an international value stock, a comparatively underserved corner of the ETF market AIVI targets, was perceived to have diminished at the observed price levels, influencing its decreasing allocation within the approximately 100-stock portfolio.
weight 0.624% → 0.599% (-0.025 pp)·stock down 6.4% in the 30 days before
Jun 16·entry 31.30·now 33.74
+7.81%
since Jun 16
AIVI · Weight decrease · 3d
Takeda Pharmaceutical (4502) recently experienced an upward shift in its share price, potentially moving it higher within its 52-week range. This price action likely prompted the AI selection engine of the WisdomTree AIVI fund, which focuses on international developed-market value stocks. The AI algorithm, continuously evaluating Takeda's valuation relative to its peers within the value-factor pool, initiated a sequence of decreases in its weight from 0.6243% on June 10, 2026, to 0.6094% by June 15, 2026. This periodic rebalancing by AIVI ensures the ETF maintains its core international value style by adjusting allocations as individual stock valuations evolve.
weight 0.624% → 0.609% (-0.015 pp)·stock down 5.5% in the 30 days before
Jun 15·entry 31.77·now 33.74
+6.20%
since Jun 15
AIVI · Weight decrease · 2d
The AIVI fund registered a consecutive decrease in its weighting for Takeda Pharmaceutical Co Ltd (4502), falling from 0.6244% on June 8th to 0.6153% by June 12th. This pattern suggests the AI selection overlay within WisdomTree's developed-international value-factor pool initiated a reduction in exposure for the Japanese pharmaceutical stock. Operating within its international value mandate, the AI's model likely re-evaluated Takeda's comparative attractiveness, determining its value contribution was diminishing relative to other approximately 100 stocks in the portfolio or to new opportunities emerging within developed markets. Given AIVI's strategy of periodic, not daily, rebalances, these observed daily shifts in weight indicate the execution of an algorithmic decision to adjust Takeda's allocation during a recent rebalancing cycle.
weight 0.624% → 0.615% (-0.009 pp)·stock down 4.0% in the 30 days before
Jun 12·entry 31.72·now 33.74
+6.38%
since Jun 12
AIVI · Weight increase · 3d
Operating within its developed-international value-factor framework, AIVI's AI likely identified Takeda Pharmaceutical Co Ltd (4502) as an initial value opportunity. The consecutive weight increases, from 0.6014% on June 4th to 0.6244% by June 8th, indicate the AI's algorithm continued to reinforce its conviction in Takeda's relative attractiveness within the fund's approximately 100-stock international developed-market portfolio. These measured adjustments, typical of AIVI's periodic rebalancing approach, reflect the AI's dynamic assessment and allocation strategy for this specific Japanese pharmaceutical company. Such moves are tailored to optimize the fund's international value exposure as evaluated by the AI.
weight 0.588% → 0.624% (+0.037 pp)
Jun 8·entry 31.55·now 33.74Drifting
+6.96%
since Jun 8
+9.77%
since Jun 5
+13.66%
since Jun 3
AIVI · Weight decrease · 2d
WisdomTree's AIVI, leveraging AI selection within its developed-international value-factor pool, adjusted its position in Takeda Pharmaceutical (4502) due to the fund's periodic rebalancing. This consecutive weight decrease, particularly the shift between May 15 and June 1, indicates the AI model identified other international developed-market value opportunities as more compelling than Takeda within its ~100-stock portfolio. The AI's analysis for this rebalance period assigned a lower relative value score to Takeda, leading to its weight falling from 0.6704% on May 15, 2026, to 0.6045% on June 1, 2026. Such a movement highlights how AIVI's AI overlay actively steers its international value strategy, causing capital reallocation when algorithms detect changes in relative attractiveness among its holdings.
weight 0.670% → 0.600% (-0.070 pp)
Jun 2·entry 30.34·now 33.74
+11.22%
since Jun 2
AIVI · Weight increase · 2d
May 15·entry 33.27·now 33.74Fresh
+1.40%
since May 15
AIVI · Weight decrease · 2d
May 11·entry 32.88·now 33.74
+2.62%
since May 11
AIVI · Weight decrease · 2d
May 6·entry 33.52·now 33.74
+0.66%
since May 6
AIVI · Accumulation · 4d
May 5·entry 33.22·now 33.74Fresh
+1.56%
since May 5
AIVI · Accumulation · 4d
May 4·entry 33.35·now 33.74Fresh
+1.16%
since May 4
AIVI · Accumulation · 3d
May 1·entry 33.44·now 33.74Fresh
+0.89%
since May 1
AIVI · Accumulation · 3d
Apr 30·entry 33.63·now 33.74Fresh
+0.33%
since Apr 30
AIVI · Weight increase · 2d
Apr 29·entry 33.03·now 33.74Drifting
+2.14%
since Apr 29
Sell signals show what the stock did after the AI exited. A negative number means the AI's exit was well-timed.